Objective Depressive symptoms seem to pose a risk factor for mortality among patients on dialysis. It is currently unknown whether the association is only short-lived and whether associations over time depend on specific causes of mortality.
INTRODUCTION
Depressive symptoms are highly prevalent in patients with end-stage renal disease (ESRD), and there is growing evidence that the presence of depressive symptoms poses a risk factor for mortality in these patients. [1] [2] [3] To understand the underlying mechanisms of depressive symptoms as a risk factor, more in-depth data about how depressive symptoms relate to mortality are needed. We currently do not know whether the effect of depressive symptoms on mortality is only short-lived or whether depressive symptoms at baseline also remain a predictor of poor survival at the long-term. There is a lack of knowledge about whether the effect of depressive symptoms on short-term mortality differs from its effect on long-term mortality because the time of follow-up in most studies was limited to 2 years. The few studies using time-varying methods, however, suggest that variations in the length of followup do influence the observed results. 4;5 Stronger effects of depressive symptoms on mortality were observed when the assessment of depressive symptoms was closer to the evaluation of medical outcomes, which may indicate that the effect of depression on mortality is only short-lived.
These findings regarding time-specific associations are important and need further clarification to understand the underlying mechanisms between depression and survival. It may provide information about the extent to whether the association can be explained by a poor somatic health that is accompanied by depressive symptoms or whether depressive symptoms result in a poor illness trajectory. If the effect of depressive symptoms on mortality is only short-lived indeed, this may suggest that the association between depressive symptoms and mortality is mainly caused by a poor somatic health. On the other hand, if depressive symptoms are especially associated with increased risk of mortality in the long-term, this may suggest that possible underlying processes unfold over time (e.g., by depressive symptoms influencing health behavior or via interactive effects on the immune system).
Besides comparing short-and long-term follow-up, it is important to distinguish between causes of mortality to explain the association between depressive symptoms and mortality.
Traditionally, there has been considerable attention for depressive symptoms as a risk factor for cardiovascular mortality [6] [7] [8] , whereas in patients with ESRD, noncardiovascular mortality may be affected by depression as well. 1;3;9 In the current study, we measured depressive symptoms in a large cohort of incident patients on hemodialysis (HD) and peritoneal dialysis (PD) participating in a Dutch nationwide study, The Netherlands Co-operative Study on the Adequacy of Dialysis (NECOSAD). Investigating the effects of depressive symptoms in a sample of patients on dialysis is important because the potential detrimental effects of depressive symptoms at the start of dialysis on mortality are not well known. To the best of our knowledge, only two studies investigated whether depressive symptoms at the start of dialysis are associated with poor survival in patients on dialysis. 4;10 The aim of the current study was to investigate the short-, medium-, and long-term effects of depressive symptoms on cardiovascular and noncardiovascular mortality.
METHODS

Patients
Data were collected within the framework of NECOSAD, a prospective observational study among incident patients on HD and PD in 38 centers in the Netherlands between 1997 and 2007. Eligible patients were older than 18 years and had no history of renal replacement therapy. The study was approved by all local medical ethics committees, and all patients gave written informed consent before inclusion. The patients were observed from the start of dialysis until death or censoring (i.e., transfer to a nonparticipating dialysis center, withdrawal from the study, renal transplantation, recovery of kidney function, or end of the follow-up period in April 2011). To allow for stabilization of laboratory data and treatment modality, the baseline measures were taken at 3 months after the start of dialysis.
Measures
The following data were collected: sociodemographics, primary cause of kidney disease (using the European Renal Association-European Dialysis and Transplant Association coding system) 11 , dialysis modality, residual glomerular filtration rate (rGFR; calculated as the mean of creatinine and urea clearance corrected for body surface area (in milliliters per minute per Depressive symptoms were assessed at baseline using the Mental Health Inventory of the Kidney Disease-Specific Quality of Life Short Form, which has been validated as a reliable measure of detecting depressive symptoms in different populations. [13] [14] [15] [16] The questionnaire includes five questions about how often during the past month patients had felt "downhearted and blue," "calm and peaceful," "happy," "nervous," and "so down in the dumps that nothing could cheer them up." Items were scored on a 6-point scale, varying from all of the time to none of the time. The reliability of the scale was good (Cronbach α = .82). The scores were summed and transformed to a scale ranging from 0 to 100. Depressive symptoms were assessed in a dichotomous manner using a cutoff of 52 (depressive symptoms present when the Mental health scores were < 52). This cutoff showed a good specificity and sensitivity for detecting depressive symptoms in chronically ill patients (i.e., sensitivity of 83%, specificity of 65%) 17 and has been used previously in patients with ESRD. 4 
End points
Causes of death were classified according to the codes of the European Renal AssociationEuropean Dialysis and Transplant Association. 11 We defined cardiovascular mortality as death due to myocardial ischemia and infarction, hyperkalemia, hypokalemia, (hypertensive) cardiac failure, fluid overload, cerebrovascular accident, hemorrhage from ruptured vascular aneurysm, cardiac arrest, or mesenteric infarction and if the cause of death was coded as unknown. We designed all other causes of mortality as being noncardiovascular, that is, infection, malignancies, suicide or refusal of further treatment, cachexia, and miscellaneous.
Statistical analysis
To compare sociodemographic and medical characteristics between patients with and without depressive symptoms, 2-tailed t tests and X² tests were conducted. Cumulative mortality curves for overall survival were calculated with competing risk analysis, taking into account cause of mortality as a competing end point. 18 Cox proportional hazard ratios (HRs) were calculated with 95% confidence intervals (95% CIs)
to assess the overall association between depressive symptoms and all-cause mortality, cardiovascular mortality, and noncardiovascular mortality up to 5 years after baseline. We also checked whether the pattern of results remained similar if depressive symptoms were analyzed as a continuous variable. To explore the association between depressive symptoms and specific causes of noncardiovascular mortality, we calculated HRs for mortality due to infection, malignancies, suicide or refusal of further treatment, and other noncardiovascular mortality separately.
To obtain a clear-cut comparison of the effects of depressive symptoms on short-and longterm mortality, HRs were calculated for three different periods after the assessment of depressive symptoms at baseline (i.e., at 3 months after starting dialysis): a) short-term mortality (0-6 months after baseline); b) medium-term mortality (6-24 months after baseline), and c) long-term mortality (24-60 months after baseline). As a consequence, medium-and long-term mortalities were conditional on having survived the previous period.
Short-, medium-, and long-term effects of depressive symptoms at baseline were assessed for all-cause mortality, cardiovascular mortality, and noncardiovascular mortality. Timedependent Cox regression analyses in which all three time periods were included were conducted to explore trends over time. 
RESULTS
Questionnaire data were available for 1528 of 1956 patients who were registered as participants at baseline (78.1%). Patients who did complete the questionnaire were more often treated with PD (p=.003), were more often white (p<.001), had relatively often glomerulonephritis (p=.004), were more often married (p=.029), tended to be younger (p=.052), and had less often cardiovascular diseases (p=.002). For all other sociodemographic and comorbidity indicators, no differences were observed.
Of the 1528 patients who completed the baseline questionnaire, 22.7% reported depressive symptoms (i.e., mental health score < 52). Patients with depressive symptoms were older, more often women, lower educated, more often nonemployed, and more often nonwhite (Table 1) . Furthermore, compared with patients without depressive symptoms, patients with depressive symptoms comprised a group of patients with a higher level of comorbidity (Davies comorbidity index, diabetes mellitus, and cardiovascular diseases) and CRP; lower levels of serum albumin, creatinine, hemoglobin, iPTH, and phosphorus; and better renal functioning (rGFR).
Depressive symptoms and mortality
For 5 years after starting dialysis treatment, 671 patients were censored before reaching the end of the study period (435 patients were transplanted, 54 patients were transferred to a nonparticipating dialysis center or the center discontinued study participation, 159 patients withdrew from the study, and 23 patients had a recovery of renal function). Patients who were transplanted during follow-up experienced less depressive symptoms (p<.001), whereas the few patients who recovered reported more depressive symptoms at baseline (p=.017). No relation between depressive symptoms at baseline and either study withdrawal To explore the association between depressive symptoms and specific causes of noncardiovascular mortality, HRs were calculated for death due to infection, malignancy, suicide or refusal of further treatment, and other noncardiovascular causes (Table 2) .
Depressive symptoms were related to all four categories of noncardiovascular causes, also after controlling for demographic and clinical variables. 
Depressive symptoms and short-, medium-, and long-term mortality
In the short-term (0-6 months), medium-term (6-24 months), and long-term (24-60 months), 86 (36 cardiovascular, 50 noncardiovascular), 229 (116 cardiovascular, 113 noncardiovascular), and 275 (122 cardiovascular, 153 noncardiovascular) deaths occurred, respectively. Depressive symptoms at baseline were associated with short-, medium-, and long-term all-cause mortality, with adjusted HRs ranging from 1.61 till 1.93 (Table 3 ). The patterns of depressive symptom-related cardiovascular and noncardiovascular mortality differed ( Table 3 ). The association between depressive symptoms and noncardiovascular mortality was present at the short, medium, and long terms. The HR for noncardiovascular mortality was most pronounced at the short-term, whereas short-term cardiovascular 
DISCUSSION
The current study provides further evidence about depressive symptoms being associated with poor survival among patients with ESRD. Importantly, during the 5-year follow-up, depressive symptoms 3 months after the initiation of dialysis were associated with a 1.5-fold increased cardiovascular mortality risk and a 2-fold increased noncardiovascular mortality risk, even after adjustment for a wide array of covariates. To the best of our knowledge, only two studies investigated the effect of depressive symptoms on mortality in incident patients on dialysis. 4;10 Consistent with our findings, Chilcot et al. 10 observed a significant association between baseline depressive symptoms and all-cause mortality. Because of a relatively small sample size (n=160), specific type of mortality was not considered in this study. In addition, Boulware et al. 4 observed an association between depressive symptoms and cardiovascular and all-cause mortality if time-varying analyses were applied. Interestingly, only noncardiovascular mortality was related to baseline depressive symptoms. Both studies reported mortality risk using a relatively short follow-up period and did not differentiate between short-and long-term mortalities.
In the current study, crude and adjusted associations between depressive symptoms at baseline and subsequent all-cause mortality were observed at short-term (0-6 months), medium-term (6-24 months), and long-term follow-up (24-60 months). Hence, in this large multicenter study of patients with ESRD, a simple assessment of patients' depressive symptoms at the start of HD or PD therapy seems to be a lasting marker of poor chances for survival. However, the patterns of results for short-, medium-, and long-term follow-up differed greatly if we considered either cardiovascular or noncardiovascular mortality: at the short-term, depressive symptoms at baseline seem to put patients especially at risk for noncardiovascular mortality, whereas increased risks of cardiovascular mortality were not observed at short-term follow-up.
These findings are important for discovering the underlying mechanism between depressive symptoms and poor survival. Several possible explanations for the association can be provided. First, the effect may be attributed to so-called reversed causality. This means that disadvanced health resulted in increased depressed symptoms, instead of depressive symptoms resulting in a poor medical trajectory. In line with this, patients with depressive symptoms comprised a group of patients with higher prevalent comorbidity at baseline already, although contrary to what would be expected from the literature 21 , renal function was better for patients with depressive symptoms. Because patient characteristics differed at baseline, we did carefully control for a large set of sociodemographic, medical, and laboratory characteristics, but this only slightly attenuated the effects we found. However, it is still possible that other comorbid disease characteristics could explain at least a part of the association between depressive symptoms and mortality. The observation that, after adjustment for a set of confounding factors, depressive symptoms did not seem to be a risk factor for cardiovascular mortality during the first 6 months is an indication that reversed causality may at least only partially explain the association between depressive symptoms and mortality.
Other suggested pathways consider the potentially bidirectional relation between depressive symptoms and immune system activity. 1;2;22 Evidence links depressive symptoms and proinflammatory cytokines [23] [24] [25] , which also play a role in the pathogenesis of cardiovascular disease. Proinflammatory cytokines related not only to cardiovascular disease but also to the occurrence of infections. Interestingly, adjusting for serum albumin and also , the burden of depressive symptoms among patients with ESRD is extensive.
Clinicians should detect and treat depressive symptoms as early as possible. The current study shows that depressive symptoms at baseline are relatively strongly related to noncardiovascular mortality in the first 6 months, which underscores that it might be vital to detect depressive symptoms in an early phase. However, there is no evidence that screening and ameliorating depressive symptoms also positively influence the risk of mortality. 36;37 Several limitations of the current study should be noted. First, not all participants of the NECOSAD study completed the questionnaires, which may influence the representativeness of the results of the whole population on dialysis. For example, responders seemed to experience cardiovascular diseases less often than did nonresponders. Second, although the 5-item Mental Health Inventory has been validated as a sound measure of depressive symptoms [13] [14] [15] [16] [17] , the scale is not commonly used as a measure of depressive symptoms in patients with ESRD. A specific strength of the mental health scale is that it does not include somatic symptoms that can be attributed to both uremic symptoms of ESRD and depression.
A practical advantage of the Mental Health Inventory is the brief format, which makes it feasible for recurrent assessments in standard care protocols.
CONCLUSION
The current study suggests that in the starting period of dialysis therapy already, depressive symptoms are a marker of subsequent mortality at the short, medium, and long terms.
Furthermore, depressive symptoms seem to pose a strong risk factor for noncardiovascular mortality at the short-term, whereas cardiovascular mortality does not increase at the shortterm yet. Hitherto, researchers have especially focused on cardiovascular pathways to understand the relation between depressive symptoms and mortality. [6] [7] [8] Our findings show that the association between depressive symptoms and specific causes of noncardiovascular mortality needs serious attention as well. Future studies should consider the effect of time and specific cause of mortality to unravel the underlying biological and psychological mechanisms.
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